Abstract 2049
Background
Resistance to chemo-radiation therapy is a substantial obstacle compromising treatment of advanced cervical cancer. We investigated if proteomic panel associated with radioresistance can predict the survival in locally advanced cervical cancer.
Methods
One hundred and eighty-one frozen tissue samples were prospectively obtained from patients with locally advanced cervical cancer before chemoradiation. To develop survival prediction model, expression of 22 total and phosphorylated proteins was evaluated by well-based reverse phase protein arrays. and selected proteins were validated by western blotting analysis and immunohistochemistry. The performance of models was internally and externally validated.
Results
Unsupervised clustering stratified patients into three major groups with different overall survival (OS, p = 0.001) and progression-free survival (PFS, p = 0.003) based on detection of BCL2, HER2, CD133, CAIX and ERCC1. reverse-phase protein array results significantly correlated with western blotting results (R2=0.856). The C-index of model was higher than clinical model in the prediction of OS (C-index of 0.86, and 0.62, respectively), and also in the prediction of PFS (C-index of 0.82, and 0.64, respectively). The Kaplan-Meier survival curve shows the dose-dependent prognostic significance of the risk score for PFS and OS. The multivariable Cox proportional hazard model confirmed that the risk score was an independent predictor of PFS (HR, 1.6; 95% CI, 1.4–1.9; p < 0.001) and OS (HR, 2.1; 95% CI, 1.7–2.5; p < 0.001).
Conclusions
A proteomic panel of BCL2, HER2, CD133, CAIX and ERCC1 independently predicted survival in locally advanced cervical cancer patients. This prediction model can help identify chemoradiation responsive tumors, and improve clinical outcome prediction in cervical cancer patients.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
Chel Hun Choi.
Funding
Samsung Medical Center.
Disclosure
The author has declared no conflicts of interest.
Resources from the same session
3034 - Efficacy and safety of neoadjuvant chemotherapy plus trastuzumab and pertuzumab in non-metastatic HER2-positive breast cancer in real life: NEOPEARL STUDY
Presenter: Maria Agnese Fabbri
Session: Poster Display session 2
Resources:
Abstract
4772 - Real world comparison of the impact of adjuvant capecitabine in women with high-risk triple-negative breast cancer after neoadjuvant chemotherapy
Presenter: Maysa Vilbert
Session: Poster Display session 2
Resources:
Abstract
5627 - Influence of age on the indication of adjuvant chemotherapy in early breast cancer using Oncotype DX. An analysis of 240 patients treated in the Institut Catala d’Oncologia (ICO) hospitals
Presenter: Sabela Recalde
Session: Poster Display session 2
Resources:
Abstract
3917 - Impact of delayed neoadjuvant systemic chemotherapy on survival among breast cancer patients
Presenter: Mariana Chavez Mac Gregor
Session: Poster Display session 2
Resources:
Abstract
2246 - Clinical Confirmation of Higher Exposure to Niraparib in Tumor vs Plasma in Patients With Breast Cancer
Presenter: Laura Spring
Session: Poster Display session 2
Resources:
Abstract
581 - The rationale for the effectiveness of systemic treatment of breast cancer depending on the body weight index
Presenter: Mohammad Hojouj
Session: Poster Display session 2
Resources:
Abstract
5327 - Response to neoadjuvant chemotherapy in HER2 non-overexpressing breast cancer subtypes
Presenter: Silvia Mihaela Ilie
Session: Poster Display session 2
Resources:
Abstract
3613 - Pre-specified interim analysis of the SAFE trial (NCT2236806): a 4-arm randomized, double-blind, controlled study evaluating the efficacy and safety of cardiotoxicity prevention in non-metastatic breast cancer patients treated with anthracyclines with or without trastuzumab.
Presenter: Lorenzo Livi
Session: Poster Display session 2
Resources:
Abstract
3736 - Safety of hypofractionated whole breast irradiation after conservative surgery for patients aged less than 60 years: a multi-center comparative study.
Presenter: Icro Meattini
Session: Poster Display session 2
Resources:
Abstract
5085 - Usefulness of NT-ProBNP as a biomarker of cardiotoxicity in breast cancer patients treated with trastuzumab
Presenter: Isabel Blancas López-Barajas
Session: Poster Display session 2
Resources:
Abstract